Neuren Pharmaceuticals Limited (OTCMKTS:NURPF – Get Free Report)’s share price traded up 4.5% on Friday . The stock traded as high as C$13.59 and last traded at C$13.59. 100 shares changed hands during mid-day trading, a decline of 90% from the average session volume of 1,049 shares. The stock had previously closed at C$13.00.
Neuren Pharmaceuticals Stock Up 4.5%
The firm’s 50 day simple moving average is C$11.20 and its two-hundred day simple moving average is C$9.07.
Neuren Pharmaceuticals Company Profile
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide), which has been registered to treat Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome.
Further Reading
- Five stocks we like better than Neuren Pharmaceuticals
- With Risk Tolerance, One Size Does Not Fit All
- Tesla’s U.S. Market Is At An 8-Year Low… How Bad Could It Get?
- Insider Buying Explained: What Investors Need to Know
- Congress: The Biggest Trades Impacting Markets Today
- How to buy stock: A step-by-step guide for beginners
- 3 Companies Boosting Buybacks While Others Pull Back
Receive News & Ratings for Neuren Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuren Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
